RESEARCH PAPER
Causes of defaulting from antiretroviral therapy and their prevention: a qualitative study of adherent clients and defaulters in Nigeria
 
More details
Hide details
1
Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria
 
2
Department of Community Medicine, University College Hospital, Ibadan, Oyo State, Nigeria
 
 
Submission date: 2020-09-09
 
 
Final revision date: 2020-11-21
 
 
Acceptance date: 2020-12-11
 
 
Publication date: 2021-06-30
 
 
HIV & AIDS Review 2021;20(2):136-143
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
In Nigeria, non-adherence to treatment or its interruption endanger successful human immunodeficiency virus (HIV) control. This study identified the causes and prevention of defaulting from antiretroviral therapy (ART) among adults on ART at Federal Medical Centre, Owo, Ondo State, Nigeria.

Material and methods:
To explore the  perspectives, thoughts, behaviors of  respondents, and new ideas, qualitative information was collected using focus group discussions (FGD) guide and in-depth interviews (IDI) guide. IDI of defaulters and FGD with persons compliant with treatment were conducted to identify the barriers to retention in care and its prevention. Data were transcribed and analyzed using the thematic framework approach.

Results:
Reasons for defaulting included traveling out of place of residence, lack of support from employer, failure to disclose HIV status to partner and caregivers. Both FGD and IDI revealed poverty/ unemployment, pill fatigue, religious factors, lack of family support, family problems, and stigmatization/discrimination, as the major reasons for defaults. Results from the FGD suggested strengthening of counselling sessions and improved follow-up to reduce defaulting.

Conclusions:
Encouraging clients to access care in health facilities, which are near their places of residence will reduce the cost of care and improve the treatment and care. Introduction of Saturday and Sunday clinic days, with options of evening visits in the evening, will promote adherence to treatment.

REFERENCES (29)
1.
Sileo KM, Wanyenze RK, Kizito W, et al. Multi-level determinants of clinic attendance and antiretroviral treatment adherence among fishermen living with HIV/AIDS in communities on Lake Victoria, Uganda. AIDS Behav 2019; 23: 406-417. .
 
2.
Erlwanger AS, Joseph J, Gotora T, et al. Patterns of HIV care clinic attendance and adherence to antiretroviral therapy among pregnant and breastfeeding women living with HIV in the context of option B+ in Zimbabwe. J Acquir Immune Defic Syndr 2017; 75: S198-S206.
 
3.
Jiamsakul A, Kerr SJ, Kiertiburanakul S, et al.; TREAT Asia HIV Observational Database (TAHOD). Early suboptimal ART adherence was associated with missed clinical visits in HIV-infected patients in Asia. AIDS Care 2018; 30: 1560-1566.
 
4.
Gokarn A, Narkhede MG, Pardeshi GS, Doibale MK. Adherence to retroviral therapy. J Assoc Physicians India 2012; 60: 16-20.
 
5.
Umeokonkwo CD, Onoka CA, Agu PA, Ossai EN, Balogun MS, Ogbonnaya NU. Retention in care and adherence to HIV and AIDS treatment in Anambra State Nigeria. BMC Infect Dis 2019; 19: 654.
 
6.
Ugwu R, Eneh A. Factors influencing adherence to paediatric antiretroviral therapy in Portharcourt, South-South Nigeria. Pan Afr Med J 2013; 16: 30.
 
7.
Ngandu NK, Jackson D, Lombard C, et al. Factors associated with non-attendance at scheduled infant follow-up visits in an observational cohort of HIV-exposed infants in South Africa, 2012-2014. BMC Infect Dis  2019; 19 (Suppl 1): 788.
 
8.
DiCarlo A, Fayorsey R, Syengo M, et al. Lay health worker experiences administering a multi-level combination intervention to improve PMTCT retention. BMC Health Serv Res 2018; 18: 17. .
 
9.
Abuogi LL, Smith C, McFarland EJ. Retention of HIV-infected children in the first 12 months of anti-retroviral therapy and predictors of attrition in resource limited settings: a systematic review. PLoS One 2016; 11: e0156506.
 
10.
Ketema AK, Weret ZS. Assessment of adherence to highly active antiretroviral therapy and associated factors among people living with HIV at Debrebrihan Referral Hospital and Health Center, northeast Ethiopia: a cross-sectional study. HIV/AIDS (Auckl) 2015; 7: 75-81.
 
11.
Reda AA, Biadgilign S. Determinants of adherence to antiretroviral therapy among HIV-infected patients in Africa. AIDS Res Treat 2012; 2012: 574656.
 
12.
AIDS Info. Guidelines for the Use of Antiretroviral Agents in Adults.
 
13.
and Adolescents with HIV. US Department of Health and Human.
 
14.
Services. 2019. Available from: https://aidsinfo.nih.gov/guide... (Accessed: 13.08.2020).
 
15.
Li H, Marley G, Ma W, et al. The role of ARV associated adverse drug reactions in influencing adherence among HIV-infected individuals: a systematic review and qualitative meta-synthesis. AIDS Behav 2017; 21: 341-351.
 
16.
Fox MP, Paascoe S, Huber AN, et al. Adherence clubs and decentralized medication delivery to support patient retention and sustained viral suppression in care: results from a cluster-randomized evaluation of differentiated ART delivery models in South Africa. PLoS Med 2019; 16: e1002874.
 
17.
Agarwal R, Rewari BB, Allam RR, Chava N, Rathore AS. Quality and effectiveness of counselling at antiretroviral therapy centers in India: capturing counsellor and beneficiary perspectives. Int Health.
 
18.
2019; 11: 480-486. .
 
19.
Zhang Y, Xu G, Hou J, et al. Problem-based learning could tackle the issue of insufficient education and adherence in people living with HIV/AIDS. Front Pharmacol 2019; 10: 901.
 
20.
Adeoti AO, Dada M, Elebiyo T, Fadare J, Ojo O. Survey of antiretroviral therapy adherence and predictors of poor adherence among HIV patients in a tertiary institution in Nigeria. Pan Afr Med.
 
21.
J 2019; 33: 277.
 
22.
Chambers LA, Rueda S, Baker DN, et al. Stigma, HIV, and health: a qualitative synthesis. BMC Public Health 2015; 15: 848.
 
23.
Barabona G, Mahiti M, Masoud S, et al. Pre-treatment and acquired HIV drug resistance in Dar es Salaam, Tanzania in the era of tenofovir and routine viral load monitoring. J Antimicrob Chemother 2019; 74: 3016-3020.
 
24.
Ndubuka NO, Lim HJ, van der Wal DM, Ehlers VJ. Health-related quality of life of antiretroviral treatment defaulters in Botswana. South Afr J HIV Med 2016; 17: 475.
 
25.
Meloni ST, Agbaji O, Chang CA, et al. The role of point-of-care viral load monitoring in achieving the target of 90% suppression in HIV-infected patients in Nigeria: study protocol for a randomized controlled trial. BMC Infect Dis 2019; 19: 368.
 
26.
Aransiola J, Imoyera W, Olowookere S, Zarowsky C. Living well with HIV in Nigeria? Stigma and survival challenges preventing optimum benefit from an ART clinic. Glob Health Promot 2014; 21: 13-22.
 
27.
Odimegwu C, Adedini SA, Ononokpono DN. HIV/AIDS stigma and utilization of voluntary counselling and testing in Nigeria. BMC Public Health 2013; 13: 465.
 
28.
Kalomo EN. Associations between HIV-related stigma, self-esteem, social support, and depressive symptoms in Namibia. Aging Ment Health 2018; 22: 1570-1576.
 
29.
Gadisa T, Tymejczyk O, Kulkarni SG, et al. Disclosure history among persons initiating antiretroviral treatment at six HIV clinics in Oromia, Ethiopia, 2012-2013. AIDS Behav 2017; 21: 70-81.
 
eISSN:1732-2707
ISSN:1730-1270
Journals System - logo
Scroll to top